FDA Grants Priority Review to Immunotherapy Combination with … – Drug Discovery & Development
Drug Discovery & Development |
FDA Grants Priority Review to Immunotherapy Combination with …
Drug Discovery & Development Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA, the company's anti-PD-1 therapy, based … FDA Grants Priority Review for Immunotherapy-Based Lung Cancer … |
